In Veritas Announces Commercial Appointment

Market Wire, June, 2006

IVMD, Inc., a novel medical device company (OTCBB: IVME), today announced the appointment of Damian Bond as commercial manager.

Damian's experience spans 18 years commercialising diagnostics, including Life Sciences, Consumer Marketing, Doctor's Office, Clinical, Food, and Environmental sectors on an international basis.

He has a strong technical knowledge of the underlying science across a number of technology platforms (Immunoassay, Molecular Biology, Microbiology, Fluorescence, Chemiluminescence, Substrate Chemistries), and an extensive record of achievement in bringing products and technologies to market.

Additionally he brings Board-level experience in both fund-raising and running VC backed technology companies as well as turning around small established companies.

His experience was gained in companies such as Unipath (now a part of the Inverness Medical group), Tepnel Life Sciences, Trinity Biotech and International Diagnostics Group plc, before founding Platform Diagnostics to develop a novel technology for digital diagnostics.

Damian said, "I am delighted to be joining IVMD. I see a great opportunity in commercialising IVMD's large product portfolio. There are a number of products waiting for good marketing partners, and with the addition of my network and knowledge that search should be made easier. IVMD's technologies move the boundaries of Point of Care diagnostics to a new level."

John Fuller, CEO said, "Damian is a great asset to the team. With our focus now on finding commercial partners for our applications, Damian has the breadth of contacts that will help us achieve our goals. His knowledge of the immunoassay market brings a new dimension to our already developed platforms and should help us achieve commercial success."

About IVMD, Inc.

IVMD uses its proven, patented core technology to design, develop and test medical devices for near patient testing and monitoring.

Our products serve large global markets in the monitoring of chronic conditions affecting large numbers of the population. Two applications form the focus of current development work. The first is a device for measuring the coagulation of blood in patients with cardiovascular disorders which is in the last stages of clinical trials. The second, a device that predicts the onset of human labour up to several weeks before birth.

Our scientists are currently working on several exciting minimally and non invasive additional products based on novel, highly sensitive immunoassays. From across all sectors of industry, our development team use our technology to create rapid prototype and product development, in partnership with major marketing and distribution partners.

IVMD actively seeks bespoke product development, manufacturing, marketing and distribution agreements.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "believe," "expects," "projects," "forecasts," "intends," "will," "anticipated," "could," or "may," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and are subject to the safe harbor created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.

Contact: IVMD (UK) Ltd. In the UK info@ivmd.com